XML 162 R44.htm IDEA: XBRL DOCUMENT v3.24.3
ORGANIZATION AND NATURE OF BUSINESS (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2023
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Financial assets   $ 64,519,982           $ 66,014,811 $ 64,519,982   $ 66,014,811 $ 68,038,621
Net loss   (2,182,534) $ (2,590,711) $ (1,866,690) $ (3,349,204) $ (981,530) $ (459,863)   (6,639,935) $ (4,790,597) (18,542,654) $ (13,830,371)
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                        
Cash                 5,331,120   5,331,120  
Fair value of common stock issued $ 138,667       $ 138,667       138,667   138,667  
Fair value of total consideration transferred                 5,469,787   5,469,787  
Financial assets   1,796,911           1,796,911 1,796,911   1,796,911  
Inventory   297,340           297,340 297,340   297,340  
Property, plant and equipment   7,488,818           7,488,818 7,488,818   7,488,818  
Identifiable intangible assets   562,200           562,200 562,200   562,200  
Financial liabilities   (3,235,233)           (3,235,233) (3,235,233)   (3,235,233)  
Total identifiable net assets   6,910,036           6,910,036 6,910,036   6,910,036  
Bargain purchase gain   $ 1,440,249           1,440,249 1,440,249   $ 1,440,249  
Revenue               344,708 549,567      
Net loss               $ (1,232,732) $ (1,674,785)